Portage Biotech Inc Financials
This page shows Portage Biotech Inc (PRTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Portage Biotech Inc reported $123.7M in net income in fiscal year 2018.
Portage Biotech Inc held $7.5M in cash against $0 in long-term debt as of fiscal year 2018.
Portage Biotech Inc had 281M shares outstanding in fiscal year 2018.
Portage Biotech Inc's ROE was 1286.4% in fiscal year 2018, measuring profit generated per dollar of shareholder equity.
PRTG Income Statement
| Metric | Q1'18 |
|---|---|
| Revenue | N/A |
| Cost of Revenue | N/A |
| Gross Profit | N/A |
| R&D Expenses | N/A |
| SG&A Expenses | N/A |
| Operating Income | N/A |
| Interest Expense | N/A |
| Income Tax | N/A |
| Net Income | N/A |
| EPS (Diluted) | N/A |
PRTG Balance Sheet
| Metric | Q1'18 |
|---|---|
| Total Assets | N/A |
| Current Assets | $7.6M |
| Cash & Equivalents | $7.5M |
| Inventory | N/A |
| Accounts Receivable | N/A |
| Goodwill | N/A |
| Total Liabilities | N/A |
| Current Liabilities | $127K |
| Long-Term Debt | N/A |
| Total Equity | $9.6M |
| Retained Earnings | -$14.3M |
PRTG Cash Flow Statement
| Metric | Q1'18 |
|---|---|
| Operating Cash Flow | N/A |
| Capital Expenditures | N/A |
| Free Cash Flow | N/A |
| Investing Cash Flow | N/A |
| Financing Cash Flow | N/A |
| Dividends Paid | N/A |
| Share Buybacks | N/A |
PRTG Financial Ratios
| Metric | Q1'18 |
|---|---|
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| Return on Equity | N/A |
| Return on Assets | N/A |
| Current Ratio | 59.97 |
| Debt-to-Equity | N/A |
| FCF Margin | N/A |
Financial Health Signals
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Similar Companies
Frequently Asked Questions
Is Portage Biotech Inc profitable?
Yes, Portage Biotech Inc (PRTG) reported a net income of $123.7M in fiscal year 2018.
What is Portage Biotech Inc's earnings per share (EPS)?
Portage Biotech Inc (PRTG) reported diluted earnings per share of $0.46 for fiscal year 2018. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Portage Biotech Inc's return on equity (ROE)?
Portage Biotech Inc (PRTG) has a return on equity of 1286.4% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.
What is Portage Biotech Inc's operating cash flow?
Portage Biotech Inc (PRTG) generated -$1.1M in operating cash flow during fiscal year 2018, representing cash generated from core business activities.
How many shares does Portage Biotech Inc have outstanding?
Portage Biotech Inc (PRTG) had 281M shares outstanding as of fiscal year 2018.
What is Portage Biotech Inc's current ratio?
Portage Biotech Inc (PRTG) had a current ratio of 59.97 as of fiscal year 2018, which is generally considered healthy.
What is Portage Biotech Inc's cash runway?
Based on fiscal year 2018 data, Portage Biotech Inc (PRTG) had $7.5M in cash against an annual operating cash burn of $1.1M. This gives an estimated cash runway of approximately 84 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Portage Biotech Inc's earnings high quality?
Portage Biotech Inc (PRTG) has an earnings quality ratio of -0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.